Re:FDA head asks for investigation into Aduhelm drug approval
by mcguire on Saturday July 10, 2021 @07:41PM
(#27797279)
[1]: "The mean age was 42 years (SD ± 15.5) and the median time since symptom onset to the inclusion was 4 days [interquartile range 3–6]. The primary outcome of hospitalization was met in 14/250 (5.6%) individuals in ivermectin group and 21/251 (8.4%) in placebo group (odds ratio 0.65; 95% confidence interval, 0.32–1.31; p = 0.227). Time to hospitalization was not statistically different between groups. The mean time from study enrollment to invasive mechanical ventilatory support (MVS) was 5.25 days (SD ± 1.71) in ivermectin group and 10 days (SD ± 2) in placebo group, (p = 0.019). There were no statistically significant differences in the other secondary outcomes including polymerase chain reaction test negativity and safety outcomes."
[ Parent
| on HN ]
Re:FDA head asks for investigation into Aduhelm drug approval
by forcry on Sunday July 11, 2021 @11:35AM
(#27801630)
Only a very low dose of Ivermectin was used. From the study limitations..
> Low percentage of hospitalization events, dose of ivermectin and not including only high-risk population.
I think one would at least use any of the protocols that were being used by the doctors who are seeing an efficacy.